Skip to Content
  • Previous Rank246
  • Revenues ($M)$39,807
  • Revenue Percent Change0.8%
  • Profits ($M)$3,920
  • Profits Percent Change-11.8%
  • Assets ($M)$95,377
  • Employees68,000

Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant’s wide-ranging portfolio was crucial to that haul–but the company’s next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb’s competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Kenneth C. Frazier
Health Care
HQ Location
Kenilworth, NJ
Years on Global 500 List23

Merck Rank History

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$39,8070.8%
Profits ($M)$3,920-11.8%
Assets ($M)$95,377-
Total Stockholder Equity ($M)$40,088-

Profit Ratios

Profit as % of Revenues9.8%
Profits as % of Assets4.1%
Profits as % of Stockholder Equity9.8%